コンテンツへスキップ
Merck

Clinical practice: Adult attention deficit-hyperactivity disorder.

The New England journal of medicine (2013-11-15)
Nora D Volkow, James M Swanson
要旨

Short-term trials involving adults with ADHD have shown significant improvements in symptoms with stimulants and atomoxetine; however, data on long-term benefits and risks of these medications, particularly among older persons, have been insufficient.

材料
製品番号
ブランド
製品内容

Supelco
アトモキセチン 塩酸塩 溶液, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
(R)-トモキセチン 塩酸塩, solid